W
William T. Leslie
Researcher at Rush University Medical Center
Publications - 28
Citations - 958
William T. Leslie is an academic researcher from Rush University Medical Center. The author has contributed to research in topics: non-small cell lung cancer (NSCLC) & Rituximab. The author has an hindex of 11, co-authored 28 publications receiving 894 citations.
Papers
More filters
Journal ArticleDOI
Age and clinical decision making in oncology patients.
TL;DR: In a tertiary care setting, older adults do not differ from their younger counterparts in terms of acceptance of chemotherapy, however, when treatment is presumed, they differ in Terms of willingness to trade survival for current quality of life.
Journal ArticleDOI
Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire.
J. M. Ribaudo,David Cella,Elizabeth A. Hahn,Stephen Lloyd,N S Tchekmedyian,J H Von Roenn,William T. Leslie +6 more
TL;DR: The reduction of the anorexia/cachexia subscale (A/CS) from 18 to 12 items was accomplished without loss of internal consistency or sensitivity to change in performance status.
Journal ArticleDOI
A phase I/II trial of intensity-modulated radiation (IMRT) dose escalation with concurrent fixed- dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer
Edgar Ben-Josef,Mathew J. Schipper,Isaac R. Francis,Scott W. Hadley,Randall Ten-Haken,Theodore Lawrence,Daniel P. Normolle,Diane M. Simeone,Christopher J. Sonnenday,Ross A. Abrams,William T. Leslie,Gazala N. Khan,Mark M. Zalupski +12 more
TL;DR: High-dose radiation therapy with concurrent FDR-G can be delivered safely and the encouraging efficacy data suggest that outcome may be improved in unresectable patients through intensification of local therapy.
Journal ArticleDOI
Selective Cyclooxygenase-2 Inhibition: A Target in Cancer Prevention and Treatment
TL;DR: Clinical studies have demonstrated the effect of COX‐2 inhibitors in the treatment of familial adenomatous polyposis, a genetic disorder that increases the risk for developing colorectal cancer.
Journal ArticleDOI
Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas.
Marcherie Davis,Kevin C. Conlon,Gerald C Bohac,John Barcenas,William T. Leslie,LaTanja Watkins,Ihab Lamzabi,Youping Deng,Yan Li,Janet M.D. Plate +9 more
TL;DR: In conclusion, innate NK-cell immunity and FoxP3+, CD8+ T cells seemed beneficial to pancreatic cancer patients and higher levels of B7-H3 expression in pancreatic tumors were detrimental to effective immunity.